Roberto Veronese

Roberto Veronese is a seasoned leader in digital health and biotech product development, with over 25 years of experience transforming scientific innovations into market-ready solutions. He has held key roles at various companies, including Vice President at Helix and Executive Director at Method, and has extensive experience in product strategy, customer experience design, and clinical integrations. artera+1

He is the founder and CEO of Accelera BIO, a product advisory firm dedicated to early- and mid-stage healthcare ventures. He also operates Veronese Ventures, an angel investment platform providing insights into his invested companies. cancercommons+1

Roberto has been instrumental in launching groundbreaking products, including GRAIL's multi-cancer early detection test (Galleri), recognized as one of TIME’s Best Inventions of 2022, and ArteraAI's AI-based cancer test, which was included in NCCN guidelines and named one of TIME’s Best Inventions of 2024. cancercommons

His educational background includes a BA and MA in Philosophy of Science from the University of Padova, complemented by executive education credentials in AI product development (MIT), healthcare management (Yale), telehealth (Stanford), and digital therapeutics (Columbia Business School). artera+1